LifeMD, Inc.
| Company Name | LifeMD, Inc. |
| Stock Symbol | LFMD |
| Class Period | May 07, 2025 to August 05, 2025 |
| Lead Plaintiff Motion Deadline | October 27, 2025 |
On August 5, 2025, after market hours, LifeMD disclosed that due to “some temporary challenges facing [its] Rex MD business,” the Company was “revising [its] full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues[.]”
On this news, LifeMD’s stock price fell $5.31, or 44.8%, to close at $6.53 per share on August 6, 2025, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3 )as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Submit Your Information
If you suffered a loss on your LifeMD, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.